Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. - Wikidata - wikimedia - TriplyDB

Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

http://www.wikidata.org/entity/Q33714897

about

Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease.Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats Calcium channel blocker enhances beneficial effects of an angiotensin II AT1 receptor blocker against cerebrovascular-renal injury in type 2 diabetic mice Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats.Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes Nuclear hormone receptors in podocytes Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial Aldosterone blockade in chronic kidney disease: can it improve outcome?Review article: eplerenone: an underused medication?Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis.The podocyte as a target for therapies--new and old.Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.Novel avenues for treating diabetic nephropathy: new investigational drugs.Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats.

P2860

Q34259981-A7367D6D-01B1-4953-94DD-A421CA71257F Q34388248-21D090FD-E352-416C-969A-2F8CA97398DF Q35067693-DD8EF9CF-3D58-463F-83A1-3C9CE6554C0D Q35138708-A08C8CF4-ED9D-4C37-AEAF-001FC7F1B3B7 Q35261898-C3DB6B90-76ED-4064-9072-65F7CD8586DC Q35842921-82441B93-08E2-411C-8FF5-D176FC71DE66 Q35894709-7D47452B-1B39-46FE-97AA-1A9764019A6A Q36079520-45FD6B6C-4141-4B3B-B50F-62E77EDA7FCE Q36236725-9DA26EDF-C6C7-45E9-BC9A-D3408967E13A Q36527306-2DD1080B-0AC3-42C5-BEE4-AEF76800CC18 Q36897652-FF78B742-606E-444F-B752-99D28012B097 Q37772047-0579CA21-7589-4E08-92A9-A267B5FEA039 Q37793666-85F53D3C-CD10-49E5-BCDB-E5368227818E Q37886981-097AB44C-0DD9-4081-8CA9-F8C23EDD980B Q37951800-E182870E-C80B-4F93-9F35-4556417B84B6 Q38072297-F10532A9-EBFF-4BE6-8E45-908B6FDFCF86 Q39170387-0D38AD00-5ABC-4436-A7F6-A191CA02AFA5 Q39517819-0F9C14B9-BFDF-404E-BA90-0984620370B7 Q48141985-16C98BF0-1873-47B9-8572-D16B635F2FED Q54463435-949649C6-803B-419B-BEC9-F54DC505BFB5

P2860

Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

http://www.wikidata.org/entity/Q33714897

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Mineralocorticoid receptor blo ...... njury in type 2 diabetic rats.

@ast

Mineralocorticoid receptor blo ...... njury in type 2 diabetic rats.

@en

type

label

Mineralocorticoid receptor blo ...... njury in type 2 diabetic rats.

@ast

Mineralocorticoid receptor blo ...... njury in type 2 diabetic rats.

@en

prefLabel

Mineralocorticoid receptor blo ...... njury in type 2 diabetic rats.

@ast

Mineralocorticoid receptor blo ...... njury in type 2 diabetic rats.

@en

P1433

Q33714897-D1B6B666-6DEB-486F-87F5-2793BDE117B9

P1476

Q33714897-DB9B7D9F-F5EC-4370-9917-9D31F4FC5589

P2093

Q33714897-40B75A3D-2CD2-4DC6-AC59-7273B4278608

Q33714897-87A0BF97-E4D1-4201-A870-78A434E4F6F2

Q33714897-9A8A5A5E-2F1F-4B27-8B15-30024372A3AE

Q33714897-9C11CF4A-5037-47E6-8986-52E700760166

Q33714897-B28BBA0C-30F5-45E1-866F-766062265447

Q33714897-CEA1A22B-3EFF-4DF2-AA00-8A5754BDDCF8

Q33714897-D502BFAB-5945-4EA6-8F9B-FEA18D2A99C3

Q33714897-DA51250F-C991-4FED-AA2F-D6EF53AD60A6

Q33714897-DDCAD505-2EF1-42B9-8B04-86C431250510

Q33714897-E855DF2E-EA18-432A-903D-2863FE9EED8E

P2860

Q33714897-050BF5D9-8DFE-4762-BF8B-CB9427BEC748

Q33714897-1052080A-BA1F-4F37-AAD4-A7B9338DCB56

Q33714897-10E4A61E-AB5B-41DE-BADE-5263F694C504

Q33714897-1281FBD9-4405-4028-85A0-53CE6843C31A

Q33714897-1867BFFF-A88A-4468-8641-2FF640DEB43C

Q33714897-1FB7664C-381E-4BC4-A058-2C650C49C6EF

Q33714897-210605EF-E922-4674-927B-B28465062B9A

Q33714897-236152D5-13B8-400A-AE10-2C9B597642D1

Q33714897-2589351C-D5B8-41A1-85FF-451AA8E36771

Q33714897-27625E44-493C-45E3-BB6A-3FE5839432BB

P304

Q33714897-EA1088FC-8598-443C-81AD-DF680FFE968B

P31

Q33714897-9F9163F1-321A-4F70-A86E-A30C3DD5258B

P356

Q33714897-1C441B74-1CF4-4C8C-A239-A489F86DBBF0

P407

Q33714897-02B917EC-AD5E-4D31-AFAA-AAF46AF37259

P433

Q33714897-C82B2113-FC1D-4ED6-AC5B-0829F07831BC

P478

Q33714897-4B008413-669C-4D14-8150-3D009E45793F

P50

Q33714897-0A188B18-6E4A-485B-9613-434025FD392F

Q33714897-DCC8C0CC-089A-4FCF-8AB3-E8A5D17D6A37

P577

Q33714897-E06D3AC5-3029-4BF7-8631-29C067B221F8

P5875

Q33714897-9CB3CBDF-CFE8-4839-B7CA-0C04137952F7

P698

Q33714897-14DFB332-525F-400C-ACCF-842D97F7C6DB

P932

Q33714897-B897F418-E702-4C1A-A676-6DE1A780DB68

P356

JPET.109.158113

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Mineralocorticoid receptor blo ...... injury in type 2 diabetic rats

@en

P2093

Akira Nishiyama

http://www.w3.org/2001/XMLSchema#string

Daisuke Nakano

http://www.w3.org/2001/XMLSchema#string

Hirofumi Hitomi

http://www.w3.org/2001/XMLSchema#string

Masahiro Hamada

http://www.w3.org/2001/XMLSchema#string

Masahito Imanishi

http://www.w3.org/2001/XMLSchema#string

Masatsugu Kishida

http://www.w3.org/2001/XMLSchema#string

Michiaki Okumura

http://www.w3.org/2001/XMLSchema#string

Naro Ohashi

http://www.w3.org/2001/XMLSchema#string

Takashi Morikawa

http://www.w3.org/2001/XMLSchema#string

Toshitaka Nakagawa

http://www.w3.org/2001/XMLSchema#string

P2860

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

Expression of podocyte-associated molecules in acquired human kidney diseases

Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor

Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats.

Eplerenone: a selective aldosterone receptor antagonist (SARA).

Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy.

Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall.

Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats.

P304

1072-1080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.109.158113

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

332

http://www.w3.org/2001/XMLSchema#string

P50

Hiroyuki Kobori

P577

2009-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40033328

http://www.w3.org/2001/XMLSchema#string

P698

19940106

http://www.w3.org/2001/XMLSchema#string

P932

2835438

http://www.w3.org/2001/XMLSchema#string